Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-04-30T13:39:42.935Z Has data issue: false hasContentIssue false
  • English
  • Français

The Neurobiology of Panic Disorder: Toward an Integrated Model

Published online by Cambridge University Press:  07 November 2014

Dan J. Stein
Dan J. Stein*
Affiliation:
Dr. Stein is professor of psychiatry and chair of the Department of Psychiatry at the University of Cape Town in South Africa and visiting professor at the University of Florida in Gainesville
*
Dan J. Stein, MD, PhD, Department of Psychiatry, J-Block, Groote Schuur Hospital, Observatory 7925, Cape Town, South Africa; Tel: +27-21-404-2164, Fax: +27-21-933-5790; E-mail: dan.stein@curie.uct.ac.za.
Get access Rights & Permissions [Opens in a new window]

Abstract

Panic disorder (PD) is a complex, multidimensional psychiatric disorder characterized by the presence of panic attacks as well as anticipatory anxiety and panic-related phobias (eg, agoraphobia). Although the etiology of this disabling disorder remains unclear, advances in basic neuroscience and in imaging studies have led to a greater understanding of the neurocircuitry and neurochemistry that are involved in modulating fear and anxiety and that are relevant to understanding PD. A preliminary integrated model can be outlined, but there is a need for additional research that cuts across genetic investigation, provocation studies, neuroimaging techniques, and treatment trials. As research continues and greater insight into the mechanisms underlying PD is achieved, additional treatment strategies may emerge.

Type
Research Article
Information
CNS Spectrums , Volume 10 , Issue S12 , September 2005 , pp. 12 - 24
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Diagnostic and Statistical Manual of Mental Disorders. 4th ed text rev. Washington, DC: American Psychiatric Association; 2000.Google Scholar
2.Biber, B, Alkin, T. Panic disorder subtypes: differential responses to CO2 challenge. Am J Psychiatry. 1999;156:739–744.CrossRefGoogle ScholarPubMed
3.Beck, JG, Shipherd, JC, Ohtake, P. Do panic symptom profiles influence response to a hypoxic challenge in patients with panic disorder? A preliminary report. Psychosom Med. 2000;62:678–683.CrossRefGoogle ScholarPubMed
4.Chambless, DL, Beck, AT, Gracely, EJ, Grisham, JR. Relationship of cognitions to fear of somatic symptoms: a test of the cognitive theory of panic. Depress Anxiety. 2000;11:1–9.Google Scholar
5.Austin, DW, Richards, JC. The catastrophic misinterpretation model of panic disorder. Behav Res Ther. 2001;39:1277–1291.CrossRefGoogle ScholarPubMed
6.Clark, DM, Salkovskis, PM, Ost, LG, et al.Misinterpretation of body sensations in panic disorder. J Consult Clin Psychol. 1997;65:203–213.CrossRefGoogle ScholarPubMed
7.Harvey, JM, Richards, JC, Dziadosz, T, Swindell, A. Misinterpretation of ambiguous stimuli in panic disorder. Cognit Ther Res. 1993;17:235–248.Google Scholar
8.McNally, RJ. Anxiety sensitivity and panic disorder. Biol Psychiatry. 2002;52:938–946.Google Scholar
9.Holt, PE, Andrews, G. Provocation of panic: three elements of the panic reaction in four anxiety disorders. Behav Res Ther. 1989;27:253–261.Google Scholar
10.Clark, DM, Salkovskis, PM, Hackmann, A, Wells, A, Ludgate, J, Gelder, M. Brief cognitive therapy for panic disorder: a randomized controlled trial. J Consult Clin Psychol. 1999;67:583–589.Google Scholar
11.Beck, AT, Sokol, L, Clark, DA, Berchick, R, Wright, F. A crossover study of focused cognitive therapy for panic disorder. Am J Psychiatry. 1992;149:778–783.Google Scholar
12.Beck, JG, Stanley, MA, Baldwin, LE, Deagle, EA III, Averill, PM. Comparison of cognitive therapy and relaxation training for panic disorder. J Consult Clin Psychol. 1994;62:818–826.CrossRefGoogle ScholarPubMed
13.Barlow, DH, Gorman, JM, Shear, MK, Woods, SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA. 2000;283:2529–2536.Google Scholar
14.Craske, MG, Maidenberg, E, Bystritsky, A. Brief cognitive-behavioral versus nondirective therapy for panic disorder. J Behav Ther Exp Psychiatry. 1995;26:113–120.CrossRefGoogle ScholarPubMed
15.Bouton, ME, Mineka, S, Barlow, DH. A modern learning theory perspective on the etiology of panic disorder. Psychol Rev. 2001;108:4–32.Google Scholar
16.Reiss, S. Expectancy model of fear, anxiety, and panic. Clin Psychol Rev. 1991;11:141–153.Google Scholar
17.Reiss, S, Peterson, RA, Gursky, DM, McNally, RJ. Anxiety sensitivity, anxiety frequency and the predictions of fearfulness. Behav Res Ther. 1986;24:1–8.CrossRefGoogle ScholarPubMed
18.Taylor, S, Koch, WJ, McNally, RJ. How does anxiety sensitivity vary across the anxiety disorders? J Anxiety Disord. 1992;6:249–259.Google Scholar
19.Schmidt, NB, Lerew, DR, Jackson, RJ. Prospective evaluation of anxiety sensitivity in the pathogenesis of panic: replication and extension. J Abnorm Psychol. 1999;108:532–537.Google Scholar
20.Schmidt, NB, Lerew, DR, Jackson, RJ. The role of anxiety sensitivity in the pathogenesis of panic: prospective evaluation of spontaneous panic attacks during acute stress. J Abnorm Psychol. 1997;106:355–364.CrossRefGoogle ScholarPubMed
21.Eke, M, McNally, RJ. Anxiety sensitivity, suffocation fear, trait anxiety, and breath-holding duration as predictors of response to carbon dioxide challenge. Behav Res Ther. 1996;34:603–607.Google Scholar
22.Rapee, RM, Brown, TA, Antony, MM, Barlow, DH. Response to hyperventilation and inhalation of 5.5% carbon dioxide-enriched air across the DSM-III-R anxiety disorders. J Abnorm Psychol. 1992;101:538–552.Google Scholar
23.Rapee, RM, Medoro, L. Fear of physical sensations and trait anxiety as mediators of the response to hyperventilation in nonclinical subjects. J Abnorm Psychol. 1994;103:693–699.Google Scholar
24.Rassovsky, Y, Kushner, MG, Schwarze, NJ, Wangensteen, OD. Psychological and physiological predictors of response to carbon dioxide challenge in individuals with panic disorder. J Abnorm Psychol. 2000;109:616–623.Google Scholar
25.Koszycki, D, Bradwejn, J. Anxiety sensitivity does not predict fearful responding to 35% carbon dioxide in patients with panic disorder. Psychiatry Res. 2001;101:137–143.CrossRefGoogle Scholar
26.Koszycki, D, Zacharko, RM, Bradwejn, J. Influence of personality on behavioral response to cholecystokinin-tetrapeptide in patients with panic disorder. Psychiatry Res. 1996;62:131–138.Google Scholar
27.Stein, MB, Jang, KL, Livesley, WJ. Heritability of anxiety sensitivity: a twin study. Am J Psychiatry. 1999;156:246–251.Google Scholar
28.Klein, DF. False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiatry. 1993;50:306–317.Google Scholar
29.Cowley, DS, Roy-Byrne, PP. Hyperventilation and panic disorder. Am J Med. 1987;83:929–937.Google Scholar
30.Forsyth, JP, Eifert, GH. Systemic alarms in fear conditioning I: a reappraisal of what is being conditioned. Behav Ther. 1996;27:441–462.Google Scholar
31.Davis, M. Neural circuitry of anxiety and stress disorders. In: Davis, KL, Charney, D, Coyle, JT, Nemeroff, C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:931–951.Google Scholar
32.Clark, DM. A cognitive model of panic attacks. In: Rachman, S, Maser, JD, eds. Panic: Psychological Perspective. Hillside, New Jersey: Erlbaum; 1988:71–89.Google Scholar
33.Rachman, S. Neo-conditioning and the classical theory of fear acquisition. Clin Psychol Rev. 1991;11:155–173.Google Scholar
34.Ayuso, JL, Alfonso, S, Rivera, A. Childhood separation anxiety and panic disorder: a comparative study. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13:665–671.CrossRefGoogle ScholarPubMed
35.Gittelman, R, Klein, DF. Relationship between separation anxiety and panic and agoraphobic disorders. Psychopathology. 1984;17(Suppl 1):56–65.Google Scholar
36.Tweed, JL, Schoenbach, VJ, George, LK, Blazer, DG. The effects of childhood parental death and divorce on six-month history of anxiety disorders. Br J Psychiatry. 1989;154:823–828.CrossRefGoogle ScholarPubMed
37.Manfro, GG, Otto, MW, McArdle, ET, et al.Relationship of antecedent stressful life events to childhood and family history of anxiety and the course of panic disorder. J Affect Disord. 1996;41:135–139.Google Scholar
38.Aschenbrand, SG, Kendall, PC, Webb, A, Safford, SM, Flannery-Schroeder, E. Is childhood separation anxiety disorder a predictor of adult panic disorder and agoraphobia? A seven-year longitudinal study. J Am Acad Child Adolesc Psychiatry. 2003;42:1478–1485.Google Scholar
39.Van der Molen, GM, van den Hout, MA, van Dieren, AC, Griez, E. Childhood separation anxiety and adult onset panic disorders. J Anxiety Disord. 1989;3:97–106.Google Scholar
40.Otto, MW, Pollack, MH, Maki, KM, et al.Childhood history of anxiety disorders among adults with social phobia: rates, correlates, and comparisons with patients with panic disorder. Depress Anxiety. 2001;14:209–213.Google Scholar
41.Stewart, CA, Petrie, RX, Balfour, DJ, Matthews, K, Reid, IC. Enhanced evoked responses after early adversity and repeated platform exposure: the neurobiology of vulnerability? Biol Psychiatry. 2004;55:868–870.CrossRefGoogle ScholarPubMed
42.Gutman, DA, Nemeroff, CB. Neurobiology of early life stress: rodent studies. Semin Clin Neuropsychiatry. 2002;7:89–95.Google Scholar
43.Charney, DS. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand Suppl. 2003;38–50.Google Scholar
44.Gutman, DA, Nemeroff, CB. Persistent central nervous system effects of an adverse early environment: clinical and preclinical studies. Physiol Behav. 2003;79:471–478.Google Scholar
45.Goodwin, RD, Eaton, WW. Asthma and the risk of panic attacks among adults in the community. Psychol Med. 2003;33:879–885.Google Scholar
46.Hasler, G, Gergen, PJ, Kleinbaum, DG, et al.Asthma and panic in young adults: a 20-year prospective community study. Am J Respir Crit Care Med. 2005;171:1224–1230.Google Scholar
47.Schmidt, NB, Telch, MJ, Jaimez, TL. Biological challenge manipulation of PCO2 levels: a test of Klein’s (1993) suffocation alarm theory of panic. J Abnorm Psychol. 1996;105:446–454.Google Scholar
48.Gorman, JM, Kent, JM, Sullivan, GM, Coplan, JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry. 2000;157:493–505.Google Scholar
49.Charney, DS, Drevets, WC. Neurobiological basis of anxiety disorders. In: Davis, KL, Charney, D, Coyle, JT, Nemeroff, C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:901–930.Google Scholar
50.Bechara, A, Tranel, D, Damasio, H, Adolphs, R, Rockland, C, Damasio, AR. Double dissociation of conditioning and declarative knowledge relative to the amygdala and hippocampus in humans. Science. 1995;269:1115–1118.Google Scholar
51.Salloway, S, White, J. Paroxysmal limbic disorders in neuropsychiatry. J Neuropsychiatry Clin Neurosci. 1997;9:403–419.Google Scholar
52.Cannistraro, PA, Rauch, SL. Neural circuitry of anxiety: evidence from structural and functional neuroimaging studies. Psychopharmacol Bull. 2003;37:8–25.Google Scholar
53.Rauch, SL, Shin, LM. Structural and functional imaging of anxiety and stress disorders. In: Davis, KL, Charney, D, Coyle, JT, Nemeroff, C, eds. Neuropsychopharmacology: The Fifth General of Progress. Nashville, Tennessee: American College of Neuropsychopharmacology; 2002:953–966.Google Scholar
54.Stewart, RS, Devous, MD Sr., Rush, AJ, Lane, L, Bonte, FJ. Cerebral blood flow changes during sodium-lactate-induced panic attacks. Am J Psychiatry. 1988;145:442–449.Google Scholar
55.Woods, SW, Koster, K, Krystal, JK, et al.Yohimbine alters regional cerebral blood flow in panic disorder. Lancet. 1988;2:678.Google Scholar
56.Reiman, EM, Raichle, ME, Robins, E, et al.Neuroanatomical correlates of a lactate-induced anxiety attack. Arch Gen Psychiatry. 1989;46:493–500.Google Scholar
57.Maddock, RJ, Buonocore, MH, Kile, SJ, Garrett, AS. Brain regions showing increased activation by threat-related words in panic disorder. Neuroreport. 2003;14:325–328.Google Scholar
58.Reiman, EM, Raichle, ME, Robins, E, et al.The application of positron emission tomography to the study of panic disorder. Am J Psychiatry. 1986;143:469–477.Google Scholar
59.De Cristofaro, MT, Sessarego, A, Pupi, A, Biondi, F, Faravelli, C. Brain perfusion abnormalities in drug-naive, lactate-sensitive panic patients: a SPECT study. Biol Psychiatry. 1993;33:505–512.Google Scholar
60.Nordahl, TE, Semple, WE, Gross, M, et al.Cerebral glucose metabolic differences in patients with panic disorder. Neuropsychopharmacology. 1990;3:261–272.Google Scholar
61.Bisaga, A, Katz, JL, Antonini, A, et al.Cerebral glucose metabolism in women with panic disorder. Am J Psychiatry. 1998;155:1178–1183.Google Scholar
62.Boshuisen, ML, Ter Horst, GJ, Paans, AM, Reinders, AA, den Boer, JA. rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. Biol Psychiatry. 2002;52:126–135.Google Scholar
63.Fontaine, R, Breton, G, Dery, R, Fontaine, S, Elie, R. Temporal lobe abnormalities in panic disorder: an MRI study. Biol Psychiatry. 1990;27:304–310.Google Scholar
64.Vythilingam, M, Anderson, ER, Goddard, A, et al.Temporal lobe volume in panic disorder--a quantitative magnetic resonance imaging study. Psychiatry Res. 2000;99:75–82.Google Scholar
65.Massana, G, Serra-Grabulosa, JM, Salgado-Pineda, P, et al.Parahippocampal gray matter density in panic disorder: a voxel-based morphometric study. Am J Psychiatry. 2003;160:566–568.Google Scholar
66.Massana, G, Serra-Grabulosa, JM, Salgado-Pineda, P, et al.Amygdalar atrophy in panic disorder patients detected by volumetric magnetic resonance imaging. Neuroimage. 2003;19:80–90.Google Scholar
67.Redmond, DE, Jr., Huang, YH. Current concepts. II. New evidence for a locus coeruleus-norepinephrine connection with anxiety. Life Sci. 1979;25:2149–2162.Google Scholar
68.Coplan, JD, Lydiard, RB. Brain circuits in panic disorder. Biol Psychiatry. 1998;44:1264–1276.Google Scholar
69.Johnson, MR, Lydiard, RB, Ballenger, JC. Panic disorder. Pathophysiology and drug treatment. Drugs. 1995;49:328–344.Google Scholar
70.Charney, DS, Heninger, GR, Breier, A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry. 1984;41:751–763.Google Scholar
71.Nesse, RM, Cameron, OG, Curtis, GC, McCann, DS, Huber-Smith, MJ. Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry. 1984;41:771–776.Google Scholar
72.Pohl, R, Yeragani, VK, Balon, R, et al.Isoproterenol-induced panic attacks. Biol Psychiatry. 1988;24:891–902.Google Scholar
73.Brambilla, F, Perna, G, Garberi, A, Nobile, P, Bellodi, L. Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. Psychoneuroendocrinology. 1995;20:1–9.Google Scholar
74.Charney, DS, Woods, SW, Krystal, JH, Nagy, LM, Heninger, GR. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand. 1992;86:273–282.Google Scholar
75.Yeragani, VK, Tancer, M, Uhde, T. Heart rate and QT interval variability: abnormal alpha-2 adrenergic function in patients with panic disorder. Psychiatry Res. 2003;121:185–196.Google Scholar
76.Abelson, JL, Glitz, D, Cameron, OG, Lee, MA, Bronzo, M, Curtis, GC. Endocrine, cardiovascular, and behavioral responses to clonidine in patients with panic disorder. Biol Psychiatry. 1992;32:18–25.Google Scholar
77.Schittecatte, M, Charles, G, Depauw, Y, Mesters, P, Wilmotte, J. Growth hormone response to clonidine in panic disorder patients. Psychiatry Res. 1988;23:147–151.Google Scholar
78.Schittecatte, M, Ansseau, M, Charles, G, et al.Growth hormone response to clonidine in male patients with panic disorder untreated by antidepressants. Psychol Med. 1992;22:1059–1062.CrossRefGoogle ScholarPubMed
79.Uhde, TW, Stein, MB, Vittone, BJ, et al.Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder. Arch Gen Psychiatry. 1989;46:170–177.Google Scholar
80.Bakker, A, van Balkom, AJ, Stein, DJ. Evidence-based pharmacotherapy of panic disorder. Int J Neuropsychopharmacol. 2005;8:473–482.Google Scholar
81.Versiani, M, Cassano, G, Perugi, G, et al.Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry. 2002;63:31–37.Google Scholar
82.Dannon, PN, Iancu, I, Grunhaus, L. The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum Psychopharmacol. 2002;17:329–333.Google Scholar
83.Seedat, S, van Rheede, vO, Muller, JE, Mohr, N, Stein, DJ. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol. 2003;18:279–284.Google Scholar
84.Bertani, A, Perna, G, Migliarese, G, et al.Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry. 2004;37:206–210.Google Scholar
85.Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators. Br J Psychiatry. 1992;160:191–202.Google Scholar
86.den Boer, JA. Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint. J Clin Psychiatry. 1998;59(Suppl 8):30–36.Google Scholar
87.Mavissakalian, M, Perel, JM. Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am J Psychiatry. 1992;149:1053–1057.Google Scholar
88.Ballenger, JC, Wheadon, DE, Steiner, M, Bushnell, W, Gergel, IP. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998;155:36–42.Google Scholar
89.Bandelow, B, Behnke, K, Lenoir, S, et al.Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry. 2004;65:405–413.Google Scholar
90.Lecrubier, Y, Judge, R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand. 1997;95:153–160.Google Scholar
91.Perna, G, Bertani, A, Caldirola, D, Smeraldi, E, Bellodi, L. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry. 2001;34:85–90.Google Scholar
92.Modigh, K, Westberg, P, Eriksson, E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1992;12:251–261.Google Scholar
93.Mavissakalian, MR. Imiprmaine vs. sertraline in panic disorder: 24-week treatment completers. Ann Clin Psychiatry. 2003;15:171–180.Google Scholar
94.Bakker, A, van Balkom, AJ, Spinhoven, P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand. 2002;106:163–167.Google Scholar
95.Otto, MW, Tuby, KS, Gould, RA, McLean, RY, Pollack, MH. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry. 2001;158:1989–1992.Google Scholar
96.Coplan, JD, Gorman, JM, Klein, DF. Serotonin related functions in panic-anxiety: a critical overview. Neuropsychopharmacology. 1992;6:189–200.Google Scholar
97.Handley, SL. 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol Ther. 1995;66:103–148.Google Scholar
98.Harvey, BH, Naciti, C, Brand, L, Stein, DJ. Serotonin and stress: protective or malevolent actions in the biobehavioral response to repeated trauma? Ann N Y Acad Sci. 2004;1032:267–272.Google Scholar
99.Evans, L, Schneider, P, Ross-Lee, L, et al.Plasma serotonin levels in agoraphobia. Am J Psychiatry. 1985;142:267.Google Scholar
100.Schneider, P, Evans, L, Ross-Lee, L, et al.Plasma biogenic amine levels in agoraphobia with panic attacks. Pharmacopsychiatry. 1987;20:102–104.Google Scholar
101.Norman, TR, Judd, FK, Burrows, GD, McIntyre, IM. Platelet serotonin uptake in panic disorder patients: a replication study. Psychiatry Res. 1989;30:63–68.Google Scholar
102.Norman, TR, Judd, FK, Gregory, M, et al.Platelet serotonin uptake in panic disorder. J Affect Disord. 1986;11:69–72.Google Scholar
103.McIntyre, IM, Judd, FK, Burrows, GD, Norman, TR. Serotonin in panic disorder: platelet uptake and concentration. Int Clin Psychopharmacol. 1989;4:1–6.Google Scholar
104.Balon, R, Pohl, R, Yeragani, V, Rainey, J, Oxenkrug, GF. Platelet serotonin levels in panic disorder. Acta Psychiatr Scand. 1987;75:315–317.Google Scholar
105.Eriksson, E, Westberg, P, Alling, C, Thuresson, K, Modigh, K. Cerebrospinal fluid levels of monoamine metabolites in panic disorder. Psychiatry Res. 1991;36:243–251.Google Scholar
106.Lesch, KP, Wiesmann, M, Hoh, A, et al.5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology (Berl). 1992;106:111–117.Google Scholar
107.Meyer, JH, Swinson, R, Kennedy, SH, Houle, S, Brown, GM. Increased left posterior parietal-temporal cortex activation after D-fenfluramine in women with panic disorder. Psychiatry Res. 2000;98:133–143.Google Scholar
108.Targum, SD, Marshall, LE. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res. 1989;28:295–306.CrossRefGoogle ScholarPubMed
109.Bell, C, Forshall, S, Adrover, M, et al.Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol. 2002;16:5–14.Google Scholar
110.Maron, E, Kuikka, JT, Shlik, J, Vasar, V, Vanninen, E, Tiihonen, J. Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Res. 2004;132:173–181.Google Scholar
111.Neumeister, A, Bain, E, Nugent, AC, et al.Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci. 2004;24:589–591.Google Scholar
112.Bakker, A, van Dyck, R, Spinhoven, P, van Balkom, AJ. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry. 1999;60:831–838.Google Scholar
113.Londborg, PD, Wolkow, R, Smith, WT, et al.Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry. 1998;173:54–60.Google Scholar
114.Pohl, RB, Wolkow, RM, Clary, CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry. 1998;155:1189–1195.Google Scholar
115.Pollack, MH, Otto, MW, Worthington, JJ, Manfro, GG, Wolkow, R. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry. 1998;55:1010–1016.Google Scholar
116.Rapaport, MH, Wolkow, R, Rubin, A, Hackett, E, Pollack, M, Ota, KY. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand. 2001;104:289–298.CrossRefGoogle ScholarPubMed
117.Leinonen, E, Lepola, U, Koponen, H, Turtonen, J, Wade, A, Lehto, H. Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci. 2000;25:25–32.Google Scholar
118.Lepola, UM, Wade, AG, Leinonen, EV, et al.A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry. 1998;59:528–534.Google Scholar
119.Stahl, SM, Gergel, I, Li, D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2003;64:1322–1327.Google Scholar
120.Ballenger, JC, Davidson, JR, Lecrubier, Y, et al.Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998;59:47–54.Google Scholar
121.Pollack, MH, Allgulander, C, Bandelow, B, et al.WCA recommendations for the long-term treatment of panic disorder. CNS Spectr. 2003;8:17–30.CrossRefGoogle ScholarPubMed
122.Geracioti, TD Jr.Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry. 1995;56:408–410.Google Scholar
123.Liebowitz, MR., Asnis, G, Tzanis, E, Whitaker, T. A placebo-controlled trial of venlafaxine XR in the short-term treatment of panic disorder. Poster presented at: Annual Meeting of the Collegium Internationale Neuropsychopharmacologicum; June 20-24, 2004; Paris, FranceGoogle Scholar
124.Papp, LA, Sinha, SS, Martinez, JM, Coplan, JD, Amchin, J, Gorman, JM. Low-dose venlafaxine treatment in panic disorder. Psychopharmacol Bull. 1998;34:207–209.Google Scholar
125.Pollack, M, Emilien, G, Tzanis, E, Whitaker, T. Venlafaxine XR and paroxetine in the short-term treatment of panic disorder. Presented at: Annual Meeting of the World Federation for the Societies of Biological Psychiatry; February 9-13, 2004; Sydney, AustraliaGoogle Scholar
126.Pollack, M, Whitaker, T, Mangano, RM, Tzanis, E. A comparison of venlafaxine XR and paroxetine in the treatment of outpatients with panic disorder. Neuropsychopharmacology. 2004;29:S201.Google Scholar
127.Pollack, MH, Worthington, JJ, Otto, MWet al.Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull. 1996;32:667–670.Google Scholar
128.Lydiard, RB, Lesser, IM, Ballenger, JC, Rubin, RT, Laraia, M, DuPont, R. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol. 1992;12:96–103.Google Scholar
129.Noyes, R Jr., Burrows, GD, Reich, JH, et al.Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry. 1996;57:349–355.Google Scholar
130.Schweizer, E, Patterson, W, Rickels, K, Rosenthal, M. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry. 1993;150:1210–1215.Google Scholar
131.Tesar, GE, Rosenbaum, JF, Pollack, MH, et al.Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry. 1991;52:69–76.Google Scholar
132.Schweizer, E, Rickels, K, Weiss, S, Zavodnick, S. Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry. 1993;50:51–60.Google Scholar
133.Roy-Byrne, P, Wingerson, DK, Radant, A, Greenblatt, DJ, Cowley, DS. Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. Am J Psychiatry. 1996;153:1444–1449.Google Scholar
134.Roy-Byrne, PP, Lewis, N, Villacres, E, et al.Preliminary evidence of benzodiazepine subsensitivity in panic disorder. Biol Psychiatry. 1989;26:744–748.Google Scholar
135.Nutt, DJ, Glue, P, Lawson, C, Wilson, S. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry. 1990;47:917–925.Google Scholar
136.Woods, SW, Charney, DS, Silver, JM, Krystal, JH, Heninger, GR. Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Res. 1991;36:115–127.Google Scholar
137.Goddard, AW, Mason, GF, Almai, A, et al.Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry. 2001;58:556–561.Google Scholar
138.Goddard, AW, Mason, GF, Appel, M, et al.Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder. Am J Psychiatry. 2004;161:2186–2193.Google Scholar
139.Malizia, AL, Cunningham, VJ, Bell, CJ, Liddle, PF, Jones, T, Nutt, DJ. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry. 1998;55:715–720.Google Scholar
140.Kaschka, W, Feistel, H, Ebert, D. Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. J Psychiatr Res. 1995;29:427–434.Google Scholar
141.Schlegel, S, Steinert, H, Bockisch, A, Hahn, K, Schloesser, R, Benkert, O. Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. A preliminary report. Eur Arch Psychiatry Clin Neurosci. 1994;244:49–51.Google Scholar
142.Abadie, P, Boulenger, JP, Benali, K, Barre, L, Zarifian, E, Baron, JC. Relationships between trait and state anxiety and the central benzodiazepine receptor: a PET study. Eur J Neurosci. 1999;11:1470–1478.Google Scholar
143.Jerabek, I, Boulenger, JP, Bradwejn, J, Lavallee, YJ, Jolicoeur, FB. CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects. Eur Neuropsychopharmacol. 1999;9:149–155.Google Scholar
144.Bradwejn, J, Koszycki, D, Shriqui, C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry. 1991;48:603–610.Google Scholar
145.Strohle, A, Holsboer, F, Rupprecht, R. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacology. 2000;22:251–256.Google Scholar
146.Lydiard, RB, Ballenger, JC, Laraia, MT, Fossey, MD, Beinfeld, MC. CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry. 1992;149:691–693.Google Scholar
147.Goldstein, S, Halbreich, U, Asnis, G, Endicott, J, Alvir, J. The hypothalamic-pituitary-adrenal system in panic disorder. Am J Psychiatry. 1987;144:1320–1323.Google Scholar
148.Holsboer, F, von Bardeleben, U, Buller, R, Heuser, I, Steiger, A. Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression, alcoholism and panic disorder. Horm Metab Res Suppl. 1987;16:80–88.Google Scholar
149.Wilkinson, DJ, Thompson, JM, Lambert, GW, et al.Sympathetic activity in patients with panic disorder at rest, under laboratory mental stress, and during panic attacks. Arch Gen Psychiatry. 1998;55:511–520.Google Scholar
150.Kathol, RG, Noyes, R Jr., Lopez, AL, Reich, JH. Relationship of urinary free cortisol levels in patients with panic disorder to symptoms of depression and agoraphobia. Psychiatry Res. 1988;24:211–221.Google Scholar
151.Coryell, W, Noyes, R. HPA axis disturbance and treatment outcome in panic disorder. Biol Psychiatry. 1988;24:762–766.Google Scholar
152.Rapaport, MH, Risch, SC, Golshan, S, Gillin, JC. Neuroendocrine effects of ovine corticotropin-releasing hormone in panic disorder patients. Biol Psychiatry. 1989;26:344–348.Google Scholar
153.Roy-Byrne, PP, Uhde, TW, Post, RM, Gallucci, W, Chrousos, GP, Gold, PW. The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiatry. 1986;143:896–899.Google Scholar
154.Coplan, JD, Pine, D, Papp, Let al.Uncoupling of the noradrenergic-hypothalamic-pituitary-adrenal axis in panic disorder patients. Neuropsychopharmacology. 1995;13:65–73.Google Scholar
155.Kendler, KS, Walters, EE, Neale, MC, et al.The structure of the genetic and environmental risk factors for six major psychiatric disorders in women. Phobia, generalized anxiety disorder, panic disorder, bulimia, major depression, and alcoholism. Arch Gen Psychiatry. 1995;52:374–383.CrossRefGoogle ScholarPubMed
156.Stein, DJ. Panic disorder. The Cognitive-Affective Neuroscience of Depression and Anxiety Disorders. London, UK: Martin Dunitz Ltd; 2003:57–69.Google Scholar
157.Papp, LA, Martinez, JM, Klein, DF, et al.Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 subjects. Am J Psychiatry. 1997;154:1557–1565.Google Scholar
158.Kent, JM, Papp, LA, Martinez, JM, et al.Specificity of panic response to CO(2) inhalation in panic disorder: a comparison with major depression and premenstrual dysphoric disorder. Am J Psychiatry. 2001;158:58–67.Google Scholar
159.Battaglia, M, Ogliari, A. Anxiety and panic: from human studies to animal research and back. Neurosci Biobehav Rev. 2005;29:169–179.Google Scholar
160.Sinha, S, Papp, LA, Gorman, JM. How study of respiratory physiology aided our understanding of abnormal brain function in panic disorder. J Affect Disord. 2000;61:191–200.Google Scholar
161.Briggs, AC, Stretch, DD, Brandon, S. Subtyping of panic disorder by symptom profile. Br J Psychiatry. 1993;163:201–209.Google Scholar
162.Nardi, AE, Nascimento, I, Valenca, AM, et al.Respiratory panic disorder subtype: acute and long-term response to nortriptyline, a noradrenergic tricyclic antidepressant. Psychiatry Res. 2003;120:283–293.Google Scholar
163.Valenca, AM, Nardi, AE, Mezzasalma, MA, et al.Therapeutic response to benzodiazepine in panic disorder subtypes. Sao Paulo Med J. 2003;121:77–80.Google Scholar
164.Bertani, A, Perna, G, Arancio, C, Caldirola, D, Bellodi, L. Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. J Clin Psychopharmacol. 1997;17:97–101.Google Scholar
165.Gorman, JM, Browne, ST, Papp, LA, et al.Effect of antipanic treatment on response to carbon dioxide. Biol Psychiatry. 1997;42:982–991.Google Scholar
166.Perna, G, Bertani, A, Caldirola, D, Gabriele, A, Cocchi, S, Bellodi, L. Antipanic drug modulation of 35% CO2 hyperreactivity and short-term treatment outcome. J Clin Psychopharmacol. 2002;22:300–308.Google Scholar
167.Bertani, A, Caldirola, D, Bussi, R, Bellodi, L, Perna, G. The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study. J Clin Psychopharmacol. 2001;21:262–267.Google Scholar
168.Bocola, V, Trecco, MD, Fabbrini, G, Paladini, C, Sollecito, A, Martucci, N. Antipanic effect of fluoxetine measured by CO2 challenge test. Biol Psychiatry. 1998;43:612–615.CrossRefGoogle ScholarPubMed
169.Schruers, K, Griez, E. The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder. J Psychopharmacol. 2004;18:553–558.Google Scholar
170.Perna, G, Bertani, A, Caldirola, D, Di Pasquale, D, Migliarese, G, Bellodi, L. Modulation of hyperreactivity to 35% CO2 after one week of treatment with paroxetine and reboxetine: a double-blind, randomized study. J Clin Psychopharmacol. 2004;24:277–282.CrossRefGoogle ScholarPubMed
171.Bertani, A, Bellodi, L, Bussi, R, Caldirola, D, Cucchi, M, Perna, G. The effect of one-week treatment with venlafaxine on 35% CO2 hyperreactivity in patients with panic disorder: an open study. J Clin Psychopharmacol. 2003;23:106–108.Google Scholar
172.Gorman, JM, Martinez, J, Coplan, JD, Kent, J, Kleber, M. The effect of successful treatment on the emotional and physiological response to carbon dioxide inhalation in patients with panic disorder. Biol Psychiatry. 2004;56:862–867.Google Scholar
173.Gorman, JM, Papp, LA, Coplan, JD, et al.Anxiogenic effects of CO2 and hyperventilation in patients with panic disorder. Am J Psychiatry. 1994;151:547–553.Google Scholar
174.Goetz, RR, Klein, DF, Papp, LA, Martinez, JM, Gorman, JM. Acute panic inventory symptoms during CO(2) inhalation and room-air hyperventilation among panic disorder patients and normal controls. Depress Anxiety. 2001;14:123–136.Google Scholar
175.Nardi, AE, Valenca, AM, Nascimento, I, Mezzasalma, MA, Zin, W. Panic disorder and hyperventilation. Arq Neuropsiquiatr. 1999;57:932–936.Google Scholar
176.Nardi, AE, Valenca, AM, Nascimento, I, Mezzasalma, MA, Zin, WA. Hyperventilation in panic disorder and social phobia. Psychopathology. 2001;34:123–127.Google Scholar
177.Nardi, AE, Valenca, AM, Nascimento, I, Zin, WA. Panic disorder and obsessive compulsive disorder in a hyperventilation challenge test. J Affect Disord. 2002;68:335–340.Google Scholar
178.Nardi, AE, Valenca, AM, Nascimento, I, Zin, WA. Hyperventilation challenge test in panic disorder and depression with panic attacks. Psychiatry Res. 2001;105:57–65.Google Scholar
179.Krystal, JH, Deutsch, DN, Charney, DS. The biological basis of panic disorder. J Clin Psychiatry. 1996;57(Suppl 10):23–31.Google Scholar
180.Liebowitz, MR, Fyer, AJ, Gorman, JM, et al.Lactate provocation of panic attacks. I. Clinical and behavioral findings. Arch Gen Psychiatry. 1984;41:764–770.Google Scholar
181.Lingjaerde, O. Lactate-induced panic attacks: possible involvement of serotonin reuptake stimulation. Acta Psychiatr Scand. 1985;72:206–208.Google Scholar
182.Nutt, D, Lawson, C. Panic attacks. A neurochemical overview of models and mechanisms. Br J Psychiatry. 1992;160:165–178.Google Scholar
183.Norman, TR, Sartor, DM, Judd, FK, et alPlatelet serotonin uptake and 3H-imipramine binding in panic disorder. J Affect Disord. 1989;17:77–81.Google Scholar
184.Cowley, DS, Dunner, DL. Response to sodium lactate in panic disorder: relationship to presenting clinical variables. Psychiatry Res. 1988;25:253–259.Google Scholar
185.Knott, VJ, Lapierre, YD. Neuropsychophysiological correlates of lactate-induced panic. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:183–192.Google Scholar
186.Yeragani, V, Balon, R, Pohl, R. Lactate infusions in panic disorder patients and normal controls: autonomic measures and subjective anxiety. Acta Psychiatr Scand. 1989;79:32–40.Google Scholar
187.Yeragani, VK, Pohl, R, Balon, R, Weinberg, P, Berchou, R, Rainey, JM. Preinfusion anxiety predicts lactate-induced panic attacks in normal controls. Psychosom Med. 1987;49:383–389.Google Scholar
188.Cowley, DS, Dager, SR, Roy-Byrne, PP, Avery, DH, Dunner, DL. Lactate vulnerability after alprazolam versus placebo treatment of panic disorder. Biol Psychiatry. 1991;30:49–56.Google Scholar
189.Liebowitz, MR, Coplan, JD, Martinez, J, et al.Effects of intravenous diazepam pretreatment on lactate-induced panic. Psychiatry Res. 1995;58:127–138.Google Scholar
190.Pohl, R, Balon, R, Berchou, R, Lycaki, H. Lactate-induced anxiety after imipramine and diazepam treatment. Anxiety. 1994;1:54–63.Google Scholar
191.Yeragani, VK, Pohl, R, Balon, R, Rainey, JM, Berchou, R, Ortiz, A. Sodium lactate infusions after treatment with tricyclic antidepressants: behavioral and physiological findings. Biol Psychiatry. 1988;24:767–774.Google Scholar
192.Keck, PE Jr., Taylor, VE, Tugrul, KC, McElroy, SL, Bennett, JA. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry. 1993;33:542–546.Google Scholar
193.Shear, MK, Fyer, AJ, Ball, G, et al.Vulnerability to sodium lactate in panic disorder patients given cognitive-behavioral therapy. Am J Psychiatry. 1991;148:795–797.Google Scholar
194.de Montigny, C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiatry. 1989;46:511–517.Google Scholar
195.Goddard, AW, Charney, DS. Toward an integrated neurobiology of panic disorder. J Clin Psychiatry. 1997;58(Suppl 2):4–11.Google Scholar
196.Zwanzger, P, Eser, D, Aicher, S, et al.Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology. 2003;28:979–984.Google Scholar
197.Zwanzger, P, Eser, D, Padberg, F, et al.Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress Anxiety. 2003;18:140–143.Google Scholar
198.Zwanzger, P, Baghai, TC, Schuele, C, et al.Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology. 2001;25:699–703.Google Scholar
199.Bradwejn, J, Koszycki, D. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry. 1994;151:261–263.Google Scholar
200.Shlik, J, Aluoja, A, Vasar, V, Vasar, E, Podar, T, Bradwejn, J. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci. 1997;22:332–340.Google Scholar
201.van Megen, HJ, Westenberg, HG, den Boer, JA, Slaap, B, Scheepmakers, A. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology (Berl). 1997;129:357–364.Google Scholar
202.Strohle, A, Kellner, M, Holsboer, F, Wiedemann, K. Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder. Am J Psychiatry. 2001;158:1514–1516.Google Scholar
203.Wiedemann, K, Jahn, H, Yassouridis, A, Kellner, M. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. Arch Gen Psychiatry. 2001;58:371–377.Google Scholar
204.Bradwejn, J, Koszycki, D, Couetoux du, TA, van Megen, H, den Boer, J, Westenberg, H. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry. 1994;51:486–493.Google Scholar
205.Kramer, MS, Cutler, NR, Ballenger, JCet al.A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry. 1995;37:462–466.Google Scholar
206.Sramek, JJ, Kramer, MS, Reines, SA, Cutler, NR. Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findings. Anxiety. 1994;1:141–143.Google Scholar
207.Hosing, VG, Schirmacher, A, Kuhlenbaumer, G, et al.Cholecystokinin- and cholecystokinin-B-receptor gene polymorphisms in panic disorder. J Neural Transm Suppl. 2004;147–156.Google Scholar
208.Miyasaka, K, Yoshida, Y, Matsushita, S, et al.Association of cholecystokinin-A receptor gene polymorphisms and panic disorder in Japanese. Am J Med Genet B Neuropsychiatr Genet. 2004;127:78–80.Google Scholar
209.Ise, K, Akiyoshi, J, Horinouchi, Y, Tsutsumi, T, Isogawa, K, Nagayama, H. Association between the CCK-A receptor gene and panic disorder. Am J Med Genet B Neuropsychiatr Genet. 2003;118:29–31.Google Scholar
210.Hamilton, SP, Slager, SL, Helleby, L, et al.No association or linkage between polymorphisms in the genes encoding cholecystokinin and the cholecystokinin B receptor and panic disorder. Mol Psychiatry. 2001;6:59–65.Google Scholar
211.Kennedy, JL, Bradwejn, J, Koszycki, D, et al.Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry. 1999;4:284–285.Google Scholar
212.Charney, DS, Woods, SW, Goodman, WK, Heninger, GR. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry. 1987;144:1030–1036.Google Scholar
213.Gurguis, GN, Uhde, TW. Plasma 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and growth hormone responses to yohimbine in panic disorder patients and normal controls. Psychoneuroendocrinology. 1990;15:217–224.Google Scholar
214.Gurguis, GN, Vitton, BJ, Uhde, TW. Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Psychiatry Res. 1997;71:27–39.Google Scholar
215.Yeragani, VK, Berger, R, Pohl, R, et al.Effects of yohimbine on heart rate variability in panic disorder patients and normal controls: a study of power spectral analysis of heart rate. J Cardiovasc Pharmacol. 1992;20:609–618.Google Scholar
216.Charney, DS, Heninger, GR. Noradrenergic function and the mechanism of action of antianxiety treatment. I. The effect of long-term alprazolam treatment. Arch Gen Psychiatry. 1985;42:458–467.Google Scholar
217.Charney, DS, Heninger, GR. Noradrenergic function and the mechanism of action of antianxiety treatment. II. The effect of long-term imipramine treatment. Arch Gen Psychiatry. 1985;42:473–481.Google Scholar
218.Goddard, AW, Woods, SW, Sholomskas, DE, et al.Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res. 1993;48:119–133.Google Scholar
219.Gurguis, GN, Antai-Otong, D, Vo, SP, et al.Adrenergic receptor function in panic disorder. I. Platelet alpha 2 receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome. Neuropsychopharmacology. 1999;20:162–176.Google Scholar
220.Yeragani, VK, Srinivasan, K, Pohl, R, Berger, R, Balon, R, Ramesh, C. Effects of nortriptyline on heart rate variability in panic disorder patients: a preliminary study using power spectral analysis of heart rate. Neuropsychobiology. 1994;29:1–7.Google Scholar
221.Charney, DS, Heninger, GR, Jatlow, PI. Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry. 1985;42:233–243.Google Scholar
222.Boulenger, JP, Uhde, TW, Wolff, EA III, Post, RM. Increased sensitivity to caffeine in patients with panic disorders. Preliminary evidence. Arch Gen Psychiatry. 1984;41:1067–1071.Google Scholar
223.Lam, P, Hong, CJ, Tsai, SJ. Association study of A2a adenosine receptor genetic polymorphism in panic disorder. Neurosci Lett. 2005;378:98–101.Google Scholar
224.Alsene, K, Deckert, J, Sand, P, de Wit, H. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology. 2003;28:1694–1702.Google Scholar
225.van West, D, Claes, S. The genteics of panic disorder: state of the art. Acta Neuropsychiatrica. 2004;16:68–78.Google Scholar
226.van den Heuvel, OA, van de Wetering, BJ, Veltman, DJ, Pauls, DL. Genetic studies of panic disorder: a review. J Clin Psychiatry. 2000;61:756–766.Google Scholar
227.Merikangas, KR, Pine, D. Genetic and other vulnerability factors for anxiety and stress disorders. In: Davis, KL, Charney, D, Coyle, JT, Nemeroff, C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. 2002:867–882.Google Scholar
228.Schwartz, CE, Wright, CI, Shin, LM, Kagan, J, Rauch, SL. Inhibited and uninhibited infants “grown up”: adult amygdalar response to novelty. Science. 2003;300:1952–1953.Google Scholar
229.Hariri, AR, Weinberger, DR. Functional neuroimaging of genetic variation in serotonergic neurotransmission. Genes Brain Behav. 2003;2:341–349.Google Scholar